{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:48:14Z","timestamp":1789264094160,"version":"build-2803163510"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.1001\/jamacardio.2019.6192","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:30:55Z","timestamp":1582716655000},"page":"576","source":"Crossref","is-referenced-by-count":58,"title":["Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span"],"prefix":"10.1001","volume":"5","author":[{"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Juraschek","sequence":"additional","affiliation":[{"name":"Section for Research, Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"hbr190026r1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015.","volume":"317","author":"Forouzanfar","year":"2017","journal-title":"JAMA"},{"issue":"21","key":"hbr190026r2","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/jama.2018.5119","article-title":"Global deaths attributable to high systolic blood pressure, 1990-2016.","volume":"319","author":"Marczak","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"hbr190026r3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jama.2019.9161","article-title":"Trends in cardiometabolic mortality in the United States, 1999-2017.","volume":"322","author":"Shah","year":"2019","journal-title":"JAMA"},{"issue":"20","key":"hbr190026r4","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1001\/jama.2019.16932","article-title":"Life expectancy and mortality rates in the United States, 1959-2017.","volume":"322","author":"Woolf","year":"2019","journal-title":"JAMA"},{"issue":"22","key":"hbr190026r5","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control.","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"hbr190026r6","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/eurheartj\/ehy770","article-title":"Limitations of hazard ratios in clinical trials.","volume":"40","author":"Stensrud","year":"2019","journal-title":"Eur Heart J"},{"issue":"23","key":"hbr190026r7","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan.","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"hbr190026r8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1740774514537404","article-title":"The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).","volume":"11","author":"Ambrosius","year":"2014","journal-title":"Clin Trials"},{"issue":"14","key":"hbr190026r9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jama.2019.11533","article-title":"Communication strategies for sharing prognostic information with patients: beyond survival statistics.","volume":"322","author":"Paladino","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"hbr190026r10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","article-title":"Restricted mean survival time as a measure to interpret clinical trial results.","volume":"2","author":"Kim","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"22","key":"hbr190026r11","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"hbr190026r12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMsa1616035","article-title":"Cost-effectiveness of intensive versus standard blood-pressure control.","volume":"377","author":"Bress","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"hbr190026r13","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2019.02.043","article-title":"Estimated long-term survival with eplerenone.","volume":"73","author":"Stienen","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"hbr190026r14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.118.033810","article-title":"Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease.","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"hbr190026r15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jash.2016.08.009","article-title":"The association between self-reported medication adherence scores and systolic blood pressure control: a SPRINT baseline data study.","volume":"10","author":"Haley","year":"2016","journal-title":"J Am Soc Hypertens"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2761951\/jamacardiology_vaduganathan_2020_br_190026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T14:00:11Z","timestamp":1589983211000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2761951"}},"subtitle":["Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)"],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.6192","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737444436.793575280","asserted-by":"object"}]},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}